Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 4/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 7/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024355 | 0.87 | SIRT2 (0.41) | ACSS2SIRT2 | |
| SCHEMBL4030987 | 0.85 | MEN1 (0.51) | SIRT2CYP1A2 | |
| SCHEMBL5678341 | 0.84 | KDM4E (0.46) | CYP3A4PLAUSIRT2CYP1A2CYP2C19 | |
| SCHEMBL5682251 | 0.83 | LMNA (0.42) | ACSS2SIRT2 | |
| SCHEMBL28415779 | 0.82 | BRD4 (0.40) | ACSS2SIRT2BAZ2BBRD4 | |
| SCHEMBL312503 | 0.82 | HPGD (0.42) | SIRT2 | |
| SCHEMBL7539383 | 0.81 | SIRT2 (0.33) | CYP3A4SIRT2CYP1A2CYP2C19 | |
| SCHEMBL4025339 | 0.81 | CYP17A1 (0.53) | ACSS2CYP17A1CYP3A4PLK1PLAU | |
| SCHEMBL4024513 | 0.80 | CA12 (0.38) | SIRT2 | |
| SCHEMBL313050 | 0.80 | ACSS2 (0.42) | ACSS2CYP17A1CYP3A4PLK1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005780-B2 | Production method of imidazole derivatives | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20160244454-A1 | PRODUCTION METHOD OF IMIDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2016-08-25 | — | — | US | disclosed |
| US-9278938-B2 | Production method of imidazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-08 | — | — | US | disclosed |
| EP-2721010-B1 | PRODUCTION METHOD OF IMIDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-2721010-A1 | PRODUCTION METHOD OF IMIDAZOLE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-20140100373-A1 | PRODUCTION METHOD OF IMIDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-10 | — | — | US | disclosed |
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| WO-2012173280-A1 | PRODUCTION METHOD OF IMIDAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-20 | — | — | WO | disclosed |
| EP-1471056-B1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
| US-8093403-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-2275411-A2 | Reformatsky Reagent in Stable Form and Process for Producing the Same | Takeda Pharmaceutical Company Limited (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-7662974-B2 | reduction of carboxylic acid ester using metal hydride complexes and metal halides to form compounds such as ethyl (3S)-3-hydroxy-3-{6-[(methylamino)carbonyl]-2-naphthyl}-3-(1-trityl-1H-imidazol-4-yl)propanoate, used as lyase enzyme inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-16 | — | — | US | disclosed |
| EP-1222174-B1 | IMIDAZOL-4-YLMETHANOLS USED AS INHIBITORS OF STEROID C17-20 LYASE | TAKEDA PHARMACEUTICAL (JP) | 2009-05-27 | — | — | EP | disclosed |
| US-20050043544-A1 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1471056-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-6649643-B1 | Antitumor, anticarcinogenic, and antimetastasis agents; benign prostatic hyperplasia, alopecia, endometriosis, uterine myoma, hirsutism, virilism, precocious puberty, mastopathy, and polycystic overay syndrome treatment | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-18 | — | — | US | disclosed |
| EP-1222174-A1 | IMIDAZOL-4-YLMETHANOLS USED AS INHIBITORS OF STEROID C17-20 LYASE | Takeda Chemical Industries, Ltd. (JP) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001030762-A1 | IMIDAZOL-4-YLMETHANOLS USE AS INHIBITORS OF STEROID C17-20 LYASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244454-A1 | PRODUCTION METHOD OF IMIDAZOLE DERIVATIVES | GRIK4, PPIP5K2, IP6K2 | ACSS2 4012/4885CYP17A1 953/4885CYP3A4 11/4885 |
| US-10005780-B2 | Production method of imidazole derivatives | GRIK4, PPIP5K2, IP6K2 | ACSS2 4012/4885CYP17A1 953/4885CYP3A4 11/4885 |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | ACSS2 1983/4885CYP17A1 1/4885CYP3A4 136/4885 |
| US-20140100373-A1 | PRODUCTION METHOD OF IMIDAZOLE DERIVATIVES | GRIK4, PPIP5K2, IP6K2 | ACSS2 4012/4885CYP17A1 953/4885CYP3A4 11/4885 |
| US-20050043544-A1 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | CYP17A1, HSD17B7, HSD17B1 | ACSS2 1989/4885CYP17A1 1/4885CYP3A4 135/4885 |
| US-20100105922-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | ACSS2 1983/4885CYP17A1 1/4885CYP3A4 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.